Post by
kuatolives on Jun 28, 2016 10:28am
Brexit
At least we don't have any UK exposure right now, unlike Merus and Concordia. Uncertainty over the Brexit for the next couple of years will likely keep those names depressed for a while, as if Concordia didn't have enough problems as it is. ARLZ is still the best name in Canadian pharma going, with maybe GUD in the mix if they actually buy something before prices rebound. No more than 13 weeks now before Yosprala gets an answer from the FDA. Could come any day now though.
Comment by
GoldenDilemma on Jun 28, 2016 12:20pm
And financials around the corner... Quite likely below $3.
Comment by
kuatolives on Jun 28, 2016 2:26pm
Nah, cash burn rate is well known and Fibricor numbers might surprise.